As shown in Table 4, there were no significant differences at baseline among the treatment groups except with regard to the bone marker carboxy-terminal collagen, which was unaccountably higher in the transdermal OptiMale USA testosterone group.
As shown in Table 4, there were no significant differences at baseline among the treatment groups except with regard to the bone marker carboxy-terminal collagen, which was unaccountably higher in the transdermal OptiMale USA testosterone group.
